Have any questions? 706-721-6582 or cts@augusta.edu
- 1951-CL-0101 A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Clinical Trial
1951-CL-0101 A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
The main purpose of this study is to determine at what dose the study drug (ASP1951 alone or ASP1951 plus pembrolizumab) is safe and tolerated and how it is processed in the blood of patients with tumors that cannotbe removed or has spread to a different part of the body. When the safe dose is identified it will be used to evaluate if the study drug treatment causes tumors to shrink in patients.
Eligibility Criteria
- Subjects must be at least 18 years of age, and have locally advanced or metastatic solid tumor malignancy that is confirmed by available pathology records or current biopsy as well as the following: Escalation cohort - has received all standard therapies felt to provide clinical benefit in the opinion of the treating investigator for his/her specific tumor type. Expnsion cohort - has received at least 1 standard therapy for his/her specific tumor type.
RESEARCH. INNOVATION. DISCOVERY.